A little history
myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.
To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:
- Development of state-of-the-art antigen prediction algorithms
- Discovery of novel, dark antigen targets called camyotopes
- (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
- The publication of high-impact scientific papers
- ISO and regulatory approval for clinical use of technology
- Securing valuable intellectual property with multiple patents
- Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
The people behind myNEO
Team
Cedric Bogaert
Chief Executive Officer & Co-founder
Bert Coessens PhD
Chief Operating Officer
Bruno Fant PhD
Chief Scientific Officer
Lien Lybaert PhD
Chief Development Officer
Lore Van Oudenhove
Chief Technology Officer
Lena Pfitzer
Senior data scientist
Gitta Boons PhD
Senior data scientist
Manon Montyne
Principal data scientist
Jens De Ceukeleire
Principal data scientist
Emiel Evenepoel
Junior bioinformatician
Marie Van Hecke PhD
Junior bioinformatician
Sofie Pontzeele
Executive assistant
Em. Prof. Kris Thielemans PhD MD
Scientific advisor
Prof. Kris Thielemans, MD, PhD, started his research career in the laboratory of Dr. R. Levy at the department of oncology of the Stanford University Medical School (CA, USA), and returned to his alma mater in Brussels (VUB), in the Laboratory of Molecular and Cellular Therapy (LMCT). In his academic research career, Kris Thielemans focused on immunotherapeutic translational research, including clinical studies for the treatment of cancer and HIV. With this team, he developed the mRNA based TriMix technology and initiated several phase I and II clinical trials in this field.
In 2013, Kris Thielemans founded eTheRNA NV. Under his stewardship, the academic research organisation was transformed into a biotechnology company by bringing different team members on board.